Original Article

Nanoencapsulation An Approach for Targeting Nasal Drug Delivery

Meghavati R. Badwar[1*], Atul R. Bendale[2], Vasim Pathan[3], Vaishali D. Naphade[4], Sandhya L. Borse[5], Hemant Chikhale[6], Laxmikant B. Borse[7]

[1*,2,3,6,7]Sandip Institute of Pharmaceutical Sciences, Nasik, Maharashtra, 422213, India
[4,5]School of Pharmaceutical Sciences, Sandip University, Nasik, Maharashtra, 422213, India

***Corresponding Author:** Meghavati R. Badwar

*Assistant Professor, Sandip Institute of Pharmaceutical Sciences, Nasik, Maharashtra, 422213, India
Contact no: 9595777450, Email: meghabadwar1207@gmail.com
Doi : 10.47750/pnr.2022.13.S05.341

Abstract

The number of issues related with oral, parenteral, rectal and different routes of drug administration. The interest of pharmaceutical researchers has expanded towards investigating the conceivable outcomes of nasal delivery of different medications. Nasal drug delivery system is ordinarily known for the treatment of nearby illnesses like cold, hack, rhinitis, and so on. Endeavors have been made to convey different medications, particularly peptides and proteins, through nasal route for initial use; using the standards and ideas of different nanoparticulate sedate conveyance frameworks utilizing different polymers and retention advertisers. The use of medications into nanoparticles may be a promising methodology, since colloidal plans have been appeared to shield them from the corrupting milieu in the nasal pit and encourage their vehicle over the mucosal obstructions. The intranasal delivery is gone for improving medication bioavailability for fundamental medications, as assimilation diminishes with expanding molecular weight, and for medications, which are powerless to enzymatic degradation, for example, proteins and polypeptides.

Keywords: Nanoencapsulation, Nasal Drug Delivery, Techniques, Applications, Factors, Nasal Cavity, Drug Absorption, Nanocarriers

BACKGROUND

Utilizing microparticles as another method for delaying the habitation time in the nasal cavity was presented in 1987. It was suggested that microspheres of egg whites, starchand DEAE-dextran (diethyl aminoethyl-dextran) consumed water and shaped a gel-like layer which was cleared gradually from the nasal cavity. Three hours after organization, half of the conveyed measure of egg whites and starch microspheres and 60% of the dextran microspheres were as yet present at the site of administration. It was proposed that an expanded contact time could build the assimilation productivity of medications. As proposed, the relative intranasal bioavailability (v.s. subcutaneous) of human development hormone in sheep was expanded from 0.1% for the answer for 2.7% for the degradable starch microsphere plan. The expansion of assimilation enhancer, lysophosphatidylcholine, further upgraded development hormone ingestion as a general bioavailability of 14.4% was accomplished.

Besides, as of late strong lipid nanoparticles have additionally indicated promising outcomes and were appeared to build the cerebrum focusing of rosmarinic corrosive after nasal conveyance for potential administration of Huntington's malady.

INTRODUCTION

Now-a-days, the nasal route of drug delivery is progressively perceived and procured. Numerous pharmaceutical products have been created for the nasal drug delivery routethat presently take points of interest of the advantages, including accommodation and convenience, fast beginning of activity, evasion of quick hepatic digestion, potential outcomes to limit systemic presentation, higher bioavailability, and quick brain access through the nerves that puncture the cribriform plate into the olfactory bulb.[1,2] These products are generally conveyed as a nasal spray, however some offer the choices of direct fluid or powder introduction. Recently, the issues related with this course of administration were altogether reviewed.[3]

ANATOMY AND PHYSIOLOGY OF NASAL CAVITY:

Anatomically, the nasal cavity can be divided into three main regions[4-9]:

Vestibular region –

It is arranged simply inside the nostrils and is secured with stratified, keratinised and squamous epithelium with sebaceous glands. It has a area of 10 to 20 cm^2 and is viewed as the least significant of the three parts in regard of medication ingestion.

Respiratory region –

It is the biggest part of the nasal cavity, has a zone of around 130 cm^2 and comprises of three turbinates in particular inferior, center and superior which are in charge of humidification and temperature guideline of breathed in air. The nasal absorption of medications is considered to happen fundamentally in the respiratory region since it is having highest level of vascularity.

Olfactory region –

It is situated in the top of the nasal cavity and on the upper portion of the nasal septum. It has a region of around 10 - 20 cm^2 and contains the receptors for the feeling of smell. Human olfactory region comprises of thick connective tissue lamina propria, where upon rests the olfactory epithelium. The cilia are non-motile in this area rather than the respiratory region since they do not have the dyne in arms which contain the Mg+2 ATPase that produces the power for ciliary motility.

The nasal cavity additionally contains nasal related lymphoid tissue (NALT). In people, the NALT is ordinarily related Waldeyerring, contains particular M-like cells which are specific for the take-up and transcytosis of macromolecules and microorganisms. Lymphoid tissue present under the nasal mucosa contains B and T lymphocyte follicles, macrophages and dendritic cells which produce foundational resistant reaction.



Figure 1 Nasal epithelium showing different cell types[66]

NANOENCAPSULATION

Nanoencapsulation is characterized as the way toward exemplifying substances with different covering materials at the nanoscale go. This method is principally utilized inside the pharmaceutical, nourishment and restorative ventures.

Advantages of Nanoencapsulation

- Protection of API from degradation.
- Targeted drug delivery with surface coating or conjugation.
- PEGylation for extended circulation time.
- Modification to surface charge can promote cell entry.
- Surface function for cell entry.
- Fluorescent labelling for imaging.

FORMULATION CONSIDERATION IN NANOENCAPSULATED NASAL DRUG DELIVERY

Notwithstanding its physiological difficulties, the nasal route offers beneficial administration contrasted with subcutaneous routes. Drug administration by the nasal route has been analyzed by numerous agents since this course takes into consideration high assimilation of low-atomic weight, hydrophobic medications, evasion of first-pass impacts and straightforwardness in organization by patients. Conveyance of nonbiocompatible, unprotected medications, and certain excipients legitimately to the fragile nasal epithelium is probably going to annoy sensitive nasal stasis, bringing about nasal irritation. In this manner, medicate details must be good with nasal physiology if the nasal route of administrationis to be utilized effectively. One strategy to get ready safe nasal formulation is to utilize smaller scale or nano-encapsulation. The size of the particles is a basic factor that influences their collaboration and transport crosswise over mucosal surfaces.[10-12]

With encapsulation and controlled release, low effective concentration of active agents can be accomplished in nasal epithelium and improve the probability of the formulation being biocompatible. The moderate discharge can result in decreased exposure of the mucosal epithelial cells, particularly if ingestion enhancers are dosed with the microcapsule so the dynamic medication can be consumed as fast as it is discharged. Two biocompatible and biodegradable polymers,

to be specific poly(D,L-lactide-co-glycolide) (PLGA) and chitosan, have been broadly utilized in epitome of dynamic substances for nasal drug delivery.[13,14]

Core materials used in nanoencapsulation

Core materials, for example, lipophilic and hydrophilic nutraceuticals compound are utilized for nanoencapsulation. Hydrophilic substances are dissolvable in water yet insoluble in lipids and natural solvents, though, lipophilic substances are insoluble in water yet soluble in lipids and natural solvents. Some nanoencapsulated hydrophilic substances are ascorbic acid, polyphenols and so on. Nanoencapsulated lipophilic substanceincorporate lycopene, beta-carotene, lutein, phytosterols and docosahexaenoicacid.[15-18]

Coating materials used for nanoencapsulation

- ***Polymers utilized in preparation of nanoparticles:*** The polymers ought to be good with the body in the terms of versatility (non-toxicity) and (non-antigenicity) and ought to be biodegradable and biocompatible.[19]
- ***Natural polymers:*** The most generally utilized characteristic polymers in arrangement of polymeric nanoparticles are Chitosan, Gelatin, Sodium alginate and Albumin.[20]
- ***Synthetic polymers:*** There are many synthetic polymers like Polylactides (PLA), Polyglycolides (PGA), Poly (lactide co-glycolides) (PLGA), Polyanhydrides, Polyorthoesters, Polycyanoacrylates, Polycaprolactone, Poly glutamic acid, Poly malic acid, Poly (N-vinyl pyrrolidone), Poly (methyl methacrylate), Poly (vinyl alcohol), Poly (acrylic acid), Poly acrylamide, Poly (ethylene glycol), Poly (methacrylic acid) etc.[21]

RATIONAL FOR DEVELOPMENT OF NASAL DELIVERY

Nasal drug delivery is a helpful delivery technique for medications that are active in low portions and demonstrate no or insignificant oral bioavailability[65]. The nasal route excuses hepatic first pass disposal related with the oral delivery. Right now, two classes of nasally conveyed therapeutics are available. The first contains low molecular weight and hydrophobic medications for the treatment of the nasal mucosa and sinus, including decongestants, topical steroids, anti-toxins and other (OTC) products. The below average envelops a couple of medications, which have adequate nasal retention for showing fundamental impacts. Significant candidates are the compounds, by and large regulated by injection and hardly absorbed after oral organization, because of their insecurity in gastrointestinal tract, poor absorption properties and their quick and broad biotransformation.

MECHANISM OF DRUG ABSORPTION THROUGH NASAL MUCOSA

- **First mechanism:** It includes a watery course of transport, which is otherwise called the paracellular course yet moderate and aloof. There is an opposite log-log relationship between's intranasal retention and the atomic load of water-solvent compounds. The atomic weight more noteworthy than 1000 Daltons having medications indicates poor bioavailability.
- **Second mechanism:** It includes transport through a lipoidal course and it is otherwise called the transcellular procedure. It is in charge of the vehicle of lipophilic medications that demonstrate a rate reliance on their lipophilicity. Drug also cross cell membranes by an active transport course by means of bearer intervened means or transport through the opening of tight junctions.

NANOENCAPSULATION TECHNIQUES[22]

Nanoencapsulation strategies use eithertop-down or bottom up methodologies for the advancement of nanomaterials.

Top-down approach

A top-down technique includes the use of precise devices that permit size drop and development forming for utilization of the nanomaterials being created. Procedures, for example, emulsification and emulsification solvent evaporation are used under the top-down methodology.

Emulsification:

The principle of emulsification includes center material which is broken down into polymerization arrangement. The monomers are polymerized to frame containers in a fluid arrangement.
Advantage: Micro or nanocapsules with narrow size distribution can be obtained.
Disadvantage: Difficult to control capsule formation

Solvent evaporation method

This technique has been done in a liquid assembling vehicle. The microcapsule coating is dissolved up in avolatilesolvent, which is immiscible with the fluid assembling vehicle phase. A core material to be microencapsulated is dissolved or scattered in the covering polymer arrangement. With agitation, the corecoating material blend is scattered in the fluid assembling vehicle phase to get the proper size nanocapsule. The blend is then warmed (if important) to vanish the dissolvable for the polymer. For the situation wherein the core material is scattered in the polymer arrangement, polymer recoils around the core. For the situation where core material is broken down in the covering polymer arrangement, a lattice - type nanocapsule is shaped. When all the dissolvable for the polymer is dissipated, the fluid vehicle temperature is decreased to encompassing temperature (whenever required) with proceeded with

unsettling. At this stage, the nanocapsules can be utilized in suspension structure, covered on to substrates or disconnected as powders. The dissolvable dissipation procedure to create nanocapsules is pertinent to a wide assortment of liquid and solidcore materials. The core materials might be either water - solvent or water - insoluble materials. An assortment of film - framing polymers can be utilized as coatings.

Bottom up approch

In the bottom up methodology, materials are built without anyone else get together and self-association of molecules, which were impacted by numerous elements including pH, temperature, concentration, and ionic strength. Supercritical liquid method, consideration complexation, coacervation, and nanoprecipitationgoes under the bottom up approach.

Complexation: In this, a specific apolar particles are entangled through a hydrophobic connection inside the β-Cyclodextrin cavity supplanting water particles.
Advantage: Efficient to secure flimsy and high included esteem apolar mixes such as flavor.
Disadvantages: i) Encapsulation limited to apolar mixes with an appropriate subatomic measurements.
ii) β-Cyclodextrin is costly.

Coacervation: In this, the capture is because of the statement of a fluid covering material around the center material by electrostatic fascination.
Advantage: Used to encapsulate heat sensitive ingredients.
Disadvantages: The complex coacervates are very flimsy, expensive and complex technique.

CHALLENGES AND OPPURTUNITIES FOR NASAL DELIVERY SYSTEMS

Existing nasal delivery devices, for example, spray pumps and pipettes can't completely exploit the depicted potential preferences of nasal delivery[47]. An enormous portion is kept on the front segment lined by skin, which isn't the objective for either topical drugs or systemic drugs. Drugs transported along the floor of the nose may cause bad taste and aggravation and decrease persistent acknowledgment. At long last, lacking and variable confirmation in the remote area lodging the openings to the sinuses and center ears, just as the olfactory locale, speaks to a genuine test for broadened utilization of nasal administration of drugs and vaccines. This applies specifically to the new progressed and costly medications requiring requesting blend of solid dosing, high patient consistence and reproducible bio-accessibility to guarantee their adequacy and security. With respect to definition, most nasal products are as of now formulated as a fluid and delivered by metered spray pumps.[48] Fluid definitions can be constrained by the solvency, security and portion volume. Powders, then again, are progressively steady and it is simpler to tweak the size and surface properties. A few investigations show reduced local irritation and more rapid absorption of powders. Bioactis Ltd. ("Bioactis"; Chief, Ryoichi Nagata, MD, PhD) has been creating nasal devices, which are therapeutic devices that deliver drugs to the nose.[49]

CURRENT APPROACHES FOR INCREASING NASAL BIOAVAILABILITY

Bioavailability of nasally administered drugs is particularly restricted by low drug solubility, rapid enzymatic degradation in nasal cavity and poor membrane penetration. Thus several approaches have been suggested to overcome these limitations.

Nasal enzyme inhibitors

Nasal metabolism of medications can be disposed of by utilizing the catalyst inhibitors. Principally for the formulation of proteins and peptide molecules advancement enzyme inhibitors like peptidases and proteases are utilized[50]. The assimilation enhancers like salts and fusidic acid subsidiaries likewise indicates protein hindrance movement to build the retention and bio-accessibility of the medication[23]. The other catalyst inhibitors usually utilized for the enzymatic action are tripsin, aprotinin, borovaline, amastatin, bestatin and boroleucin inhibitors.[24]

Permeation enhancers

The permeation enhancers are predominantly utilized for enhancing the absorption of the active medicament[51]. In general, the absorption enhancers act by means of one of the mechanism mentioned below:

- Inhibit enzyme activity;
- Reduce bodily fluid consistency or flexibility;
- Decrease mucociliary clearance;
- Open tight intersections; and
- Solubilize or balance out the medication.

The mechanism of action of absorption enhancer is expanding the rate at which medication goes through the nasal mucosa. Numerous enhancers demonstration by adjusting the structure of epithelial cells somehow or another, yet they ought to achieve this while making no harm or lasting change nasal mucosa.

Ideal characteristics of penetration enhancer[52]

- Drug it should be a compelling increment.

- It ought not make permanant harm or modification the tissues
- It ought to be non-irritant and nontoxic.
- It ought to be successful in little amount
- At the time of absorption the enhancing effect should occur.
- The impact ought to be brief and reversible
- It ought to be compatible with different excipients.

Different kinds of penetration enhancers have been assessed for natural medications including surfactants, bile salts, chelators, unsaturated fatty acid salts, phospholipids, glycyrrhetenic acid derivatives, cyclodextrins and glycols.



Figure 2 Classification of chemical penetration enhancer[53]

Prodrug approach

Prodrug approach is primarily implied for optimization of physicochemical properties, for example, solubility, taste, odour, stability, and so forth. Prodrug is normally alluded as promoiety, it is to cover the undesired functional groups with another functional groups. This prodrug approach is essentially for improving the nasal bioavailability particularly for the proteins and peptides to increase the permeability of membrane and also enzymatic stability[54]. The prodrug experiences enzymatic change to discharge the dynamic medicament, when it crosses the enzymatic and film obstruction. The assimilation of peptides like angiotensin II, bradykinin, caulein, carnosine, enkepha-lin, vasopressin and calcitonin are improved by prepared into enamine subsidiaries, these specialists indicated absorption enhancement with prodrug approach[55].

Structural modification

Alteration of medication structure without modifying pharmacological movement is one of the worthwhile approaches to improve the nasal retention. The modification of drug molecule has been regularly used to adjust the physicochemical properties of a medication, for example, sub-atomic size, sub-atomic weight, pka and dissolvability to improve the nasal ingestion of medication. For example, alteration of salmon calcitonin to ecatonin (C-N bond replaces the S-S bond) demonstrated preferable bioavailability over salmon calcitonin.[25]

Particulate drug delivery

Molecule configuration is an inexorably significant role in improvement of absorption. Microspheres, nanoparticles and liposomes are can be utilized as transporters to encapsulate an active drug. The properties of these can be changed to boost remedial adequacy. In general, this can result in expanded assimilation adequacy and security and diminished poisonous quality of the therapeutic efficacy. Systems can be intended to be mucoadhesive to expand the maintenance time and encourage supported discharge. Microspheres are fundamentally increment the ingestion and bioavailability by adhering to the nasal mucosa and increment the nasal residence time of medication. The microspheres formulated by utilizing polymers like dextran, chitosan, biodegradable starch microspheres effectively improved the bioavailability of different medications. Liposomes are amphiphilic in nature are characterized for penetration of medications through the biological membranes, so the water dissolvable medications have been conveyed to nasal medications. Cationic liposomes are having great permeation capacity than adversely charged anionic liposomes.[26]

EVALUATION OF NANOENCAPSULATED NASAL DRUG DELIVERY

Nanoparticle size determination

The particle size and polydispersityindex (PDI) of all nanoparticles were dictated by dynamic light scattering (DLS) utilizing Malvern Zetasizer. For DLS estimations, the formulation were diluted with refined water separated at 0.45 µm to keep away from various dispersing. The investigation was performed at 25°C and at a 90° scattering angle[56].

Surface charge determination

The surface charge of the nanoparticles was estimated utilizing phase analysis light dispersing. Similar examples were utilized for both size and zeta potential assurance, with a similar instrument[57]. For every estimation, nanoparticles were diluted with refined water sifted at 0.45 μm to accomplish an ideal conductance without changing the surface charge properties of nanoparticles.

Nanoparticle tracking analysis (NTA)

In order to further affirm the particle size distribution and have an assessment of particle concentration in suspension, a nanoparticles tracking analysis (NTA) experiment was directed utilizing NanoSight NS300 (Malvern Instruments Ltd.) outfitted with a 480 nm laser light source, and a 20× amplification magnifying lens was utilized to complete the particle tracking analysis with a field of perspective on around 100×80×10 μm. The implicit sCMOS camera was utilized to record recordings, and the particle tracking was analyzed byby NTA 3.1 programming.[58]

Imaging of nanoparticle using scanning electron microscopy (SEM)

The morphology of raw material and formulation was observed by scanning transmission electron microscopy (STEM).

Determination of nanoparticle structure and interaction with a nasal mucus model by SAXS

The internal structure of nanoparticles and the structural changes occuring upon their interaction with a model of nasal bodily fluid were examined by Synchrotron small-angle X-ray scattering (SAXS) technique[59]. The X-beam cross segment was 200×400 μm with λ=0.1 nm. All estimations were performed at T=25°C. Test samples were placed in plastic capillaries with 2 mm internal diameter, mounted on a level plane onto a thermostated test holder.

The encapsulation efficiency (EE)

The encapsulation efficiency (EE) of nanoparticles was determined by anindirect method; that is, the amount of precipitated and free medication were evaluated and subtracted from the total sum of the medication measured in the total preparation, and all sums were dictated by HPLC, and afterward expressed as a percentage of the total drug in the preparation.[60]

In vitro drug release from LCNs

In vitro release from nanocapsules was studied utilizing simulated nasal electrolytic solution (SNES) containing potassium, calcium, and sodium at biologic human convergences of the nasal liquid. A volume of 1 mL of the nanoemulsion was diluted with 1 mL of SNES at pH 6.5 and placed in the dialysis bags[61]. The sealed bags were drenched into 100 mL of the release medium containing 0.5% BSA kept at 37°C and magnetically mixed at required rpm. At predetermined time points aliquots of the disintegration medium were taken and replaced with a proportional measure of fresh release medium. Samples were analyzed by HPLC to determine the released medication.

APPLICATIONS OF NANOENCAPSULATION

Intranasal administration for vaccine delivery[27-31]

Nanocarriers have some qualities that make them one of a kind as immunization adjuvants. Initially, these nanocarriers are one of the main adjuvants that can successfully build the measure of antigen that achieves the immune system. Besides, nanocarriers can control the arrival of the antigen over prolonged period of time. Along these lines this impacts the antigen accessibility after some time, and through that, likewise results in safe reaction. Thirdly, the nanocarriers can join their primary function as antigen delivery system with different impacts, for example, immunostimulation and immunomodulation. So as to accomplish a methodical arrangement, the nanocarriers are isolated into lipid-based nanocarriers and polymeric nanocarriers. A few example have been cited for the delivery of nanocarriers by means of intranasal administration like, PLA-PEG nanoparticles which have potential for the nasal delivery of nucleic corrosive antibodies. Numerous difficulties stay ahead, the expanding learning about the immune system, the developing field of nano-drug and the use of new nanotechnologies together with a progressively positive view towards the advantages of mucosal immunization by administrative experts, wellbeing experts and researchers, imagine the future landing of another age of intranasal antibodies.

The readers may have a review on licenses for intranasal conveyance by Misra et al. (2008). There are additionally licenses which depict that how the nanoparticulate medicate conveyance is affecting the specialists and pharmaceutical enterprises to create definitions by means of intranasal organization.

Polymeric nanoparticles in view of their size are specially taken up by the mucosa related lymphoid tissue. They are broadly assessed for nasal organization. Hsing-wen et al., 2009 displayed a development which is identified with therapeutic utilization of nanoparticles having a pharmaceutical organization of chitosan and polyglutamic corrosive with bioactive operators and conveyance methods for nasal organization for upgraded penetrability.

Soane et al., 1999 have arranged nasal flu immunization utilizing chitosan. Nasal flu immunization may demonstrate to be a decent option in contrast to parenteral infusion in view of the upgrade of the mucosal resistant reaction and the

simplicity of antibody organization. This examination researched the utilization of chitosan, a bioadhesive polymer, as a nasal conveyance framework with inactivated, subunit flu immunization.

Table 1 Some examples of Intranasal Vaccines formulated in Nanocarrier

Antigen	Nanocarrier Formulation	Conclusions
Cholera toxin	Multiple emulsion	Higher titre both qualitatively and quantitatively in mucosal membranes and systemic circulation
Tetanus toxoid	Liposomes	Intranasal administration was found effective for inducing mucosal immunity
Toxoplasma gondii, Tachyzoites	Micro/ Nanoparticles	Increased levels and higher mucosal and systemic immunity
Plasmid DNA	Cationic nanoparticles	25-30 fold higher beta-galactosidase response

Intranasal administration for direct brain delivery[32-37]

This segment reports examination of the transport pathways of medications from the nasal cavity to the CNS, perceptions were made on transport route of therapeutic drugs from nasal administration. It has been found in animal models that expanding the medication atomic weight, hydrophilicity and level of ionization can diminish medication transport into the CNS after intranasal administration. Along these lines, transport of a medication legitimately into the CSF, as a measure for CNS conveyance, is controlled by a blend of atomic and natural properties of the medication which are at this stage hard to anticipate. At last, various examinations have demonstrated that CNS bioavailability of low sub-atomic weight tranquilizes after intranasal instillation is extremely low. Direct nose-to-mind conveyance of various medications will be reliant on different assimilation pathways. The lipophilic medication will be retained into the circulation system through typical freedom components. The medications additionally reaches to the cerebrum from blood by intersection BBB, however can likewise be wiped out from the CSF into the blood. The medication gets ingested from the nose by means of the olfactory locale into the CSF and conceivably further to the cerebrum. The medication retention or medications lost by means of various pathways are very subject to the qualities of medication. At the point when medications are managed nasally the medication will typically be cleared by the mucociliaryclearance system at the same time, the above assimilation pathways for medications restrain leeway by mucociliaryclearance system. The utilization of nanoparticles may offer an improvement to nose-to-cerebrum medicate conveyance since they can shield the epitomized medication from organic or potentially synthetic debasement, and extracellular transport by P-gp efflux proteins. This would build CNS accessibility of the medication.

Intranasal route for systemic delivery[38-40]

The intranasal delivery is a compelling method to systemically convey drugs as an alternative to oral and intravascular routes as it offers the potential for quick ingestion and quick beginning of activity, while maintaining a strategic distance from hepatic first pass digestion. Potential applications incorporate the treatment of acute pain, nausea and vomiting. Some systemic medications, for example, calcitonin, desmopressin, painkillers as morphine and against headache mixes are now promoted in nasal details. As of recently no nanoparticulate intranasal detailing is accessible in market as, the analysts have concentrated on the delivery system to make it for explicit focusing in sick conditions. The clinical utilization of macromolecular medications connected nasally is expanding bit by bit and these medications are planned for non-parenteral application thinking about their clinical favorable position and cost of improvement. The atomic weight of these medications is between 1,000-3,400 Da and nasal bioavailability is roughly 10% which causes these medications as a decent contender to create in to nanoparticulate formulation for nasal delivery.

Table 2 Marketed Intranasal formulation

Drug Molecule	Brand	Company	Indications
Salmon Calcitonin	Miacalcin®	Novartis, USA	Postmenopausal Osteoporosis treatment
Estradiol	Aerodiol®	Servier Laboratories, France	Hormone replacement therapy (HRT)
Desmopressin	Desmospray®	Ferring Pharmaceuticals, US	Control of dehydration in Diabetes Insipidus
Nicotine	Nicotrol NS®	Pfizer, USA	Smoking cessation
Sumatriptan	Imigran®	GlaxoSmithKline, USA	Migraine and cluster
Zolmitriptan	Zomig Nasal®	AstraZeneca, USA	Migraine and Cluster headache

Efficacy and transport of nanoparticles/nanoemulsion/ microemulsion[41,42]

The drug delivery perspective has shown application of nanoparticles composed of polymers and this shows measurably more prominent capacity, than a simple solution of the medication, to convey model medications, for example, nimodipine to the olfactory bulb or to upgrade the pharmacological movement of morphine, when these little particles are connected intranasally in mix with nanoparticles. Consequently, noteworthy upgrade of nimodipine conveyance to the CSF and olfactory bulb has been accounted for when intranasally connected to rodents in methoxy-PEG-PLA (MPEG-PLA) nanoparticles (76.5 nm width) contrasted with medication in arrangement. The examination demonstrated a reliance of the vehicle on the size and surface characteristics of the nanoparticles and the kind of cell culture utilized. Generally extremely low amounts of particles were transported through both of the cell cultures, the littler particles were transported to a higher degree than the bigger particles and aminated particles were transported through co-culture systems superior to carboxylated particles.

Table 3 Intranasally Administered Nanocarrier Formulations

Drug	Type of Formulation	Results
Clonazepam	Microemulsion	Accumulation and transport of drug in brain
Risperidone	Nanoemulsion	Risperidone quickly and effectively delivered to brain by intranasal administration
Sumatriptan	Microemulsion	Accumulation of drug in brain via nasal administration
Ulexeuropeus Agglutinin	PEG-PLA nanoparticles	Results as potential carriers for brain delivery

Recent developments in nanoencapsulated nasal drug delivery system

Agustin Diaz et al. [43], studied Nanoencapsulation of Insulin into Zirconium Phosphate for Oral Delivery Applications. In this examination in vitro release profile of the hormone after the intercalation was resolved and roundabout dichroism was utilized to think about the hormone stability upon intercalation and release. The insulin stays stable in the layered material, at room temperature, for a lot of time, improving the shell life of the peptidic hormone. This sort of material represents to a strong candidate to building up a noninvasive insulin transporter for the treatment of diabetes mellitus.

Clementino A et al. [44], studied the nasal delivery of nanoencapsulated statins – an approach for brain delivery. The SVT-LCNs developed presented the absolute most desirable qualities for mucosal conveyance, that is, little particle size, positive surface charge, long term stability, high encapsulation efficiency, and mucoadhesion. What's more, they showed two energizing highlights: First was their biodegradability by chemicals present in the mucous layer, for example, lysozyme. This demonstrates another Trojan-horse system which may improve medication discharge in the nearness of the nasal mucosa. Second was their capacity to upgrade the nose-to-mind transport as prove by fundamental gamma scintigraphy studies.

Sonvico F et al. [45], studied Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. In this survey, nanomedicine delivery dependent on particle building abusing surface electrostatic charges, mucoadhesive polymers, or chemical moieties focusing on the nasal epithelium will be examined and basically assessed in connection to nose-to-brain conveyance.

Salatin S et al.[62], studied Hydrogel nanoparticles and nanocomposites fornasal drug/vaccine delivery.The examination endeavors have extensively been coordinated towards the advancement of hydrogel nanosystems which have mucoadhesive properties so as to expand the living arrangement time, and subsequently increment the time of contact with the nasal mucosa and improve the medication retention. It is most sure that the high consistency of hydrogel-based nanosystems can effectively offer this mucoadhesive property. This survey discusses about the potential advantages of utilizing hydrogel polymer-based nanoparticles and hydrogel nanocomposites for medication/antibody conveyance through the intranasal administration.

Csaba N et al.[63], studied Nanoparticles for nasalvaccination. The utilization of nanocarriers gives a reasonable path to the nasal delivery of antigenic particles. Other than improved security and encouraged transport of the antigen, nanoparticulate conveyance frameworks could likewise give progressively viable antigen acknowledgment by insusceptible cells. These represent to key factors in the ideal handling and introduction of the antigen, and consequently in the resulting improvement of an appropriate safe reaction. In this sense, the plan of advanced antibody nanocarriers offers a promising route for nasal mucosal inoculation.

Ali J et al.[64], studied Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration. This review examines the potential advantages of utilizing nanoparticles for nasal delivery of medications and antibodies for brain systemic and topical delivery. This article giving a knowledge inside nasal cavity, thought of variables influencing and methodologies to improve drug absorption through nasal route, pharmaceutical dose structures and delivery systems with instances of certain patents for intranasal delivery, its benefits and constraints.

Csaba N et al. [46], studied PLGA: Poloxamer and PLGA: Poloxamine blend nanostructures as carriers for nasal gene delivery. In this work arrangement of another sort of nanoparticles comprising of blends of poly (lactic-co-glycolic corrosive) (PLGA) and polyethylene oxide (PEO) derivatives; which show the ability to associate and release plasmid DNA in a controlled way. The objective of study is to examine the capacity of these nanoparticles to overcome cell and mucosal boundaries (for example nasal mucosa) and therefore, to function as quality conveyance bearers. The outcomes propose that these new nanoparticles have a potential as transporters for the conveyance of DNA over the nasal mucosa.

CONCLUSION

Bioavailability of nasally administered medications is especially confined by low drug solubility, quick enzymatic degradation in nasal cavity, and poor membrane penetration. Nasal drug delivery is a useful technique for medications that are active in low portions and demonstrate no or insignificant oral bioavailability. The nasal delivery excuses hepatic first pass transfer related with the oral delivery.Nanoencapsulation offers Protection to API from degradation. It gives targeted drug delivery with surface coting or conjugation. Although some brain-targeted on nanoparticles loaded with statins have been proposed by some different writers, this is to our knowledge the first research proposing nanoparticles to be administered nasally to deliver statins to the brain.The particles were designed to optimized the loading of a lipophilic drugs and to give various features helpful to nasal delivery, for example, physical and chemical stability, biocompatibility, mucoadhesion, and a quick medication release. Although further studies are important to

explain if the nanoparticles are taken up by the nasal epithelium or essentially support the medication absorption without crossing the mucosa and to research the pharmacokinetics and efficacy of the nanoformulated statin after administration via the nasal route.Nanomedicines appears to be a essential tool to enable the brain delivery of potent drug unable to cross the BBB and when utilized all things considered they will satisfy the potential showed in the numerous scientific studies conducted so far.

REFERENCES

1. Illum, L., 2003. Nasal drug delivery: possibilities, problems and solutions. J. Control. Release 87, 187–198.
2. Langer, R., 1998. Drug delivery and targeting. Nature 392, 5–10.
3. Law, J., 2000. Not to be sniffed at. Scrip 5, 35–38.
4. Chien, Y.W., Chang, S., Su, K., 1989. Nasal Systemic Drug Delivery, 39th ed. Marcel Dekker, New York.
5. Hochestrasser, K., 1983. Proteinases and their inhibitors in human nasal mucus. Rhinology21, 217.
6. Scott, W.T., McKenna, M.J., 1985. Hydrolysis of several glycol ether acetates and acrylate esters by nasal mucosal carboxylesterase in vitro. Fundam. Appl. Toxicol. 5, 399.
7. Lee, V.H.L., 1988. Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Ther. Drug Carrier Syst. 5, 69–97. Reed, C.J., 1993.
8. Drug metabolisim in the nasal cavity: relevance to toxicology. Drug Metab. Rev. 25, 173–205.
9. Thorne, R.G., Frey, W.H., 2001. Delivery of neurotrophic factors to the central nervous system. Clin. Pharmacokinet. 40, 907–946.
10. Jian, X.G., Cui, J.B., Fang, X.L., 1995. Toxicity of drugs on nasal mucocilia and the methodof its evaluation. Acta Pharm. Sinica 30, 848–853.
11. Martin, E., Schipper, N.G.M., Verhoef, J.C., Merkus, F.W.H.M., 1998. Nasal mucociliaryclearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 29, 13–38.
12. Martin, E., Verhoef, J.C., Spies, F., 1999. The effect of methylated beta-cyclodextrin on thetight junctions of the rat nasal respiratory epithelium: electron microscope and confocallaser scanning microscope visualization studies. J. Control. Release 57, 205–213.
13. Ramanthan, R., Geary, R., Bourne, D.W., Putcha, L., 1998. Bioavailability of intranasalpromethazine dosage forms in dogs. Pharm. Res. 38 (1), 35–39.
14. Young, J.T., 1981. Histopathologic examination of rat nasal cavity. Fundam. Appl. Toxicol.1, 309–312.
15. Lopez A, Gavara R, and Lagaron J, Bioactive packaging: turning foods into healthier foods through biomaterials, Trends in Food Science and Technology, 2006; 17(10): 567–575.
16. Lakkis J M, Encapsulation and controlled release technologies in food systems, Iowa: Blackwell, 2007.
17. Heyang J, Fei X, Cuilan J, Yaping Z and Lin H, Nanoencapsulation of lutein with hydroxypropylmethyl cellulose phthalate by supercritical antisolvent, Chinese Journal of Chemical Engineering, 2009; 17(4): 672–677.
18. Zimet P, and Livney Y D, Beta-lactoglobulin and its nanocomplexes with pectin as vehicles for ω-3 polyunsaturated fatty acids, Food Hydrocolloid, 2009; 23(4): 1120–1126.
19. Leong W F, Lai O M, Long K, Yaakob B, Mana C, Misran M and Tan C P, Preparation and characterization of water-soluble phytosterolnanodispersions, Food Chemistry, 2011; 129(1): 77–83.
20. Ghosh P K, Hydrophilic polymeric nanoparticles as drug carriers, Indian Journal of Biochemistry and Biophysics, 2000; 37: 273-282.
21. Nagavarma B V N, Hemant K S Yadav, Ayaz A, Vasudha L S, Shivakumar H G. "Different techniques for preparation of polymeric nanoparticles- a review". Asian Journal of Pharmaceutical and Clinical Research. 2012; 5 (3): 16-23.
22. Augustin M A and Sanguansri P, Nanostructured materials in the food industry, Advances in Food and Nutrition Research, 2009; 58(4): 183–213.
23. Hussain MA, Koval CA, ShenviAB, Aungst BJ, Recovery of rat nasal mucosa from the effects of aminopepti-dase inhibitors. J Pharm Sci 1990;79:398-400
24. Donnelly A, Kellaway IW\, Taylor G, Gibson M. Absorption enhancers as tools to determine the route of nasal absorption of peptides.J Drug Target 1998;5:121-7
25. Hofstee BH. Specificity of esterase. II.Behavior of pancreatic esterase I and II toward a homologous series of N-fatty acid esters. J BiolChem 1952; 199:365-71
26. Chien Y.W., Su K.S.E., Chang S.F., Nasal Systemic Drug Delivery, Ch. 1, Marcel-Dekker, New York, 1-77, 1989.
27. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccinedelivery. Adv Drug Deliv Rev 2008 ; 60 : 915-28.
28. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drugand gene delivery to cells and tissue, Adv Drug Deliv Rev 2003;55: 329-47.
29. Vila A, Sanchez A, Perez C, Alonso MJ. Pla-peg nanospheres: newcarriers for transmucosal delivery of proteins and plasmid DNA.PolymAdvTechnol 2002; 13: 851-8.
30. Csaba N, Sanchez A, Fernandez-Megia E, Novoa-Carballal R,Alonso MJ. Chitosan nanoparticles for the delivery of plasmidDNA: preparation and characterisation. Eur J Pharm Sci 2004; 23:54.
31. Fernandez UR, Romani D, Calvo P, Vila JJL, Alonso MJ.Development of a freeze-dried formulation of insulin-loadedchitosan nanoparticles intended for nasal administration. STPPharmaSci 1999; 9: 429-36.
32. Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T.Direct drug transport from the rat nasal cavity to the cerebrospinalfluid: the relation to the molecular weight of drugs. J PharmPharmacol 1995; 47: 379-81.
33. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, SezakiH. The transport of a drug to the cerebrospinal fluid directly fromthe nasal cavity the relation to the lipophilicity of the drug. ChemPharm Bull 1991; 39: 2456-8.
34. Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T. Direct drugtransport from the rat nasal to the cerebrospinal fluid: the relationto the dissociation of the drug. J Pharm Pharmacol 1994; 46: 378-9.
35. Chou KJ, Donovan MD. Distribution of antihistamines into theCSF following intranasal delivery. Biopharm Drug Dispos 1997;18: 335-46.
36. Dahlin M, Jansson B, Bjork E. Levels of dopamine in blood andbrain following nasal administration to rats. Eur J Pharm Sci 2001;14: 75-80.
37. Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E,*et al.* Transfer of morphine along the olfactory pathway to thecentral nervous system after nasal administration to rodents. Eur JPharm Sci 2005; 24: 565-73.
38. Illum L. Nasal drug delivery: possibilities, problems and solutions.J Control Release 2003; 87: 187-98.
39. Illum L. Nasal drug delivery: new, developments and strategies.Drug Discov Today 2002; 7: 1184-9.
40. Stoke DG, Reber KR, Waltzman LS, Erns C, Hamilton D,Gawareck D, *et al*. Analgesic efficacy and safety of morphinechitosannasal solution in patients with moderate to severe painfollowing orthopedic surgery. Pain Med 2008; 9: 3-12.
41. Zhang QZ, Zha LS, Zhang Y, Jiang WM, Lu W, Shi ZQ, *et al*. Thebrain targeting efficiency following nasally applied MPEG-PLAnanoparticles in rats. J Drug Targ 2006; 14: 281-90.
42. Betbeder D, Sperandio S, Latapie JP, Nadai J, Etienne A, ZajacJM, *et al*. Biovector (tm) nanoparticles improve antinociceptiveefficacy of nasal morphine. Pharm Res 2000; 17: 743-8.
43. Agustın Dıaz at al., Nanoencapsulation of Insulin into Zirconium Phosphate for Oral Delivery Applications,Biomacromolecules2010, 11, 2465–2470.
44. Adryana Clementino1et al.,The nasal delivery of nanoencapsulated statins – an approach for brain delivery, International Journal of Nanomedicine, 2016:11 6575–6590.
45. Fabio Sonvico et al.,Surface-Modified Nanocarriers for Nose-to-BrainDelivery: From Bioadhesion to Targeting, Pharmaceutics 2018, 10, 34.

46. N. Csaba, A. Sánchez, M.J. Alonso, PLGA: Poloxamer and PLGA: Poloxamine blend nanostructures as carriers for nasal gene delivery, Journal of Controlled Release 113 (2006) 164–172.
47. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013 Feb;3(1):42-62. doi: 10.1007/s13346-012-0108-9. Epub 2012 Oct 18. PMID: 23316447; PMCID: PMC3539067.
48. Nirav S Sheth, Rajan B Mistry. A Review: Nasal Drug Delivery System. Research J. Pharm. and Tech. 4(3): March 2011; Page 349-355.
49. Dhakar, Ram C. (2011). Non-invasive Systemic Drug Delivery via Nasal Route: A Review. The African Journal of Pharmaceutical Sciences and Pharmacy. 2. 114-144.
50. Morimoto K, Yamaguchi H, Iwakura Y, Miyazaki M, Nakatani E, Iwamoto T, Ohashi Y, Nakai Y. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm Res. 1991 Sep;8(9):1175-9. doi: 10.1023/a:1015862603939. PMID: 1724082.
51. Rassu G, Ferraro L, Pavan B, Giunchedi P, Gavini E, Dalpiaz A. The Role of Combined Penetration Enhancers in Nasal Microspheres on In Vivo Drug Bioavailability. Pharmaceutics. 2018 Oct 26;10(4):206. doi: 10.3390/pharmaceutics10040206. PMID: 30373187; PMCID: PMC6321492.
52. Davis, Stanley & Illum, Lisbeth. (2003). Absorption Enhancers for Nasal Drug Delivery. Clinical pharmacokinetics. 42. 1107-28. 10.2165/00003088-200342130-00003.
53. Dragicevic, N., Atkinson, J.P., Maibach, H.I. (2015). Chemical Penetration Enhancers: Classification and Mode of Action. In: Dragicevic, N., Maibach, H. (eds) Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47039-8_2
54. Tirucherai GS, Yang C, Mitra AK. Prodrugs in nasal drug delivery. Expert Opin Biol Ther. 2001 Jan;1(1):49-66. doi: 10.1517/14712598.1.1.49. PMID: 11727547.
55. Martins PP, Smyth HDC, Cui Z. Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm. 2019 Oct 30;570:118635. doi: 10.1016/j.ijpharm.2019.118635. Epub 2019 Aug 21. PMID: 31445062.
56. Carney, R., Kim, J., Qian, H. *et al.* Determination of nanoparticle size distribution together with density or molecular weight by 2D analytical ultracentrifugation. *Nat Commun* **2**, 335 (2011). https://doi.org/10.1038/ncomms1338
57. Rasmussen, M.K., Pedersen, J.N. & Marie, R. Size and surface charge characterization of nanoparticles with a salt gradient. *Nat Commun* **11**, 2337 (2020). https://doi.org/10.1038/s41467-020-15889-3
58. Kim, A., Ng, W.B., Bernt, W. *et al.* Validation of Size Estimation of Nanoparticle Tracking Analysis on Polydisperse Macromolecule Assembly. *Sci Rep* **9**, 2639 (2019). https://doi.org/10.1038/s41598-019-38915-x
59. Adryana Rocha Clementino, Giulia Pellegrini, Sabrina Banella, Gaia Colombo, Laura Cantù, Fabio Sonvico, and Elena Del Favero, *Molecular Pharmaceutics* **2021** *18* (8), 3132-3146 DOI: 10.1021/acs.molpharmaceut.1c00366
60. Piacentini, E. (2016). Encapsulation Efficiency. In: Drioli, E., Giorno, L. (eds) Encyclopedia of Membranes. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44324-8_1945
61. Abdel-Mottaleb MM, Neumann D, Lamprecht A. In vitro drug release mechanism from lipid nanocapsules (LNC). Int J Pharm. 2010 May 10;390(2):208-13. doi: 10.1016/j.ijpharm.2010.02.001. Epub 2010 Feb 10. PMID: 20149853.
62. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Milani MA, Jelvehgari M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. Arch Pharm Res. 2016 Sep;39(9):1181-92. doi: 10.1007/s12272-016-0782-0. Epub 2016 Jun 28. PMID: 27352214.
63. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57. doi: 10.1016/j.addr.2008.09.005. Epub 2008 Dec 13. PMID: 19121350.
64. Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, Bhavna. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des. 2010 May;16(14):1644-53. doi: 10.2174/138161210791164108. PMID: 20210751.
65. Sarode, Surajj & Barhate, S. & Patil, P. & Usman, Md & Bendale, Atul. (2017). Preparation and evaluation of mucoadhesive buccal tablet for oral infection disease. Journal of Pharmaceutical and BioSciences. 5. 38. 10.31555/jpbs/2017/5/4/38-43.
66. Mona Khan, at. al, Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb, Cell, 184 (24), 2021, 5932-5949.e15, https://doi.org/10.1016/j.cell.2021.10.027.